Vaccination protects not just the person receiving the shot, but everyone around them.
For nearly three decades, McMaster University's Mark Loeb has pursued a quiet but consequential question — how do we prevent infectious disease from taking lives — and the answers he has found have quietly rewritten public health policy across the globe. This week, the Canadian Medical Association recognized that lifelong pursuit with its highest honour, the F.N.G. Starr Award, acknowledging a career that spans influenza, COVID-19, antimicrobial resistance, and beyond. His work reminds us that the most profound medical advances are often not dramatic breakthroughs but the patient accumulation of rigorous evidence, applied where it matters most.
- With antimicrobial resistance emerging as one of the defining health crises of our era, Loeb's globally adopted prescribing standards offer a rare, evidence-based foothold against a threat that grows more urgent each year.
- His landmark Hutterite colony trial upended assumptions about who benefits from vaccination, proving that a child's flu shot can shield a vulnerable elder across the room — a finding that forced policy revisions in multiple countries.
- When COVID-19 fractured scientific consensus and public trust, Loeb ran the rigorous international trials the moment demanded, producing mask-guidance evidence that shaped WHO and CDC recommendations under intense public scrutiny.
- Over 450 peer-reviewed publications and $30 million in secured funding represent not just personal achievement but a sustained institutional argument that infectious disease research deserves serious, long-term investment.
- The F.N.G. Starr Award lands as formal confirmation of what health systems worldwide have already quietly enacted — that Loeb's research has moved from academic journals into the living architecture of global public health.
Mark Loeb has spent nearly thirty years asking a deceptively simple question: how do we stop infectious diseases from killing people? The answer has reshaped medicine on six continents, and this week the Canadian Medical Association recognized that work with its highest honour — the F.N.G. Starr Award for lifetime achievement in medicine.
Loeb, a professor of pathology and molecular medicine at McMaster University, has authored more than 450 peer-reviewed papers, delivered over 300 invited lectures worldwide, and secured more than $30 million in research funding. But the numbers obscure what actually matters. His most consequential contribution may be in demonstrating that vaccination protects not just the individual, but entire communities. A landmark trial in Canadian Hutterite colonies provided the strongest evidence to date that vaccinating children against influenza generates herd immunity — a finding published in JAMA that changed immunization policy in multiple countries.
He also uncovered something unexpected: flu shots save lives in ways medicine hadn't previously measured. A trial spanning more than 5,000 participants across ten countries found that vaccinating heart failure patients reduced cardiovascular deaths during influenza season by 23 percent. A later meta-analysis of over 670,000 patients confirmed that flu vaccination prevents death and hospitalization even when it fails to prevent infection entirely.
When COVID-19 arrived, Loeb led international randomized controlled trials comparing surgical masks with N95 respirators — work that drew intense scrutiny but ultimately informed guidance from the WHO and the CDC. He has also investigated SARS, West Nile virus, dengue, and mpox throughout his career.
Perhaps his most enduring legacy lies in antibiotic stewardship. Working with the WHO, he helped develop the AWaRe antibiotic classification system and created the 'Loeb Minimum Criteria' for antibiotic use in long-term care — standards now used worldwide to slow antimicrobial resistance. In accepting the award, Loeb framed his career not as individual achievement but as collective effort. The honour is a formal acknowledgment of what his research has already accomplished: reshaping how the world responds to infectious disease.
Mark Loeb has spent nearly thirty years asking a deceptively simple question: how do we stop infectious diseases from killing people? The answer, it turns out, has reshaped medicine on six continents.
Loeb, a professor of pathology and molecular medicine at McMaster University, was awarded the F.N.G. Starr Award this week—the highest honour the Canadian Medical Association bestows. The prize recognizes lifetime achievement that has fundamentally altered how medicine is practiced and how public health is understood. In Loeb's case, that recognition rests on a body of work so extensive it reads almost like a chronicle of modern epidemiology: more than 450 peer-reviewed papers, over 300 invited lectures delivered to audiences worldwide, and more than $30 million in research funding secured as principal investigator. His citations appear in health policy documents and clinical guidelines across continents.
But the numbers, while impressive, obscure what actually matters. Loeb's most consequential work has been in demonstrating that vaccination does something most people don't fully grasp: it protects not just the person receiving the shot, but everyone around them. A landmark clinical trial he led in Canadian Hutterite colonies provided the strongest evidence to date that vaccinating children against influenza creates herd immunity—a protective shield that extends to infants, the elderly, and the immunocompromised. That finding, published in the Journal of the American Medical Association, changed immunization policy in multiple countries.
He then turned his attention to an unexpected discovery: flu shots save lives in ways we hadn't measured before. In a trial spanning more than 5,000 participants across ten countries, Loeb's team found that vaccinating patients with heart failure reduced cardiovascular deaths during influenza season by 23 percent. The vaccine wasn't just preventing infection; it was preventing the cascade of cardiac events that infection can trigger. More recently, a systematic review and meta-analysis he co-led examined data from hundreds of studies involving more than 670,000 patients worldwide, proving that flu vaccination prevents death and hospitalization even when it fails to prevent infection entirely.
When COVID-19 arrived, Loeb did what he had always done: he designed rigorous randomized controlled trials to answer urgent questions. While the world argued about masks, he led international studies comparing surgical masks with N95 respirators, generating the kind of high-quality evidence that informed guidance from the World Health Organization and the U.S. Centers for Disease Control and Prevention. The work drew intense scrutiny, but he persisted.
Beyond influenza and COVID-19, Loeb has investigated SARS, West Nile virus, dengue, and mpox. But perhaps his most enduring contribution may be in a different arena entirely: antibiotic stewardship. Working with the World Health Organization, he helped develop the AWaRe classification system for antibiotics—now adopted globally. He also created what are known as the "Loeb Minimum Criteria" for antibiotic use in long-term care homes, a set of standards now used worldwide to combat antimicrobial resistance. Recently, he leveraged this work to shape Canada-specific antimicrobial prescribing recommendations commissioned by the Public Health Agency of Canada.
In his acceptance remarks, Loeb emphasized gratitude—to his research team at McMaster, to his colleagues, to the institutions that supported the work. He framed his career not as individual achievement but as collective effort toward a single goal: preventing and treating infectious diseases. That framing matters. The F.N.G. Starr Award recognizes individuals whose work has profoundly influenced medicine, science, and humanity. In Loeb's case, the influence is measurable in policy changes across continents, in lives saved through better vaccination practices, in the slowing of antimicrobial resistance. The award is a formal acknowledgment of what his research has already accomplished: reshaping how the world responds to infectious disease.
Notable Quotes
It has been a great privilege to conduct research to prevent and treat infectious diseases and I am extremely grateful to my McMaster research team and my colleagues in contributing to findings that have had an important impact, not only in Canada, but globally.— Mark Loeb
For almost three decades, Dr. Mark Loeb has been at the forefront of research on infectious disease, championing public health interventions which have saved the lives of countless individuals worldwide.— Paul O'Byrne, vice-president of the Faculty of Health Sciences and dean of the Michael G. DeGroote School of Medicine
The Hearth Conversation Another angle on the story
What made Loeb's Hutterite colonies study so important? It seems like a specific finding about one community.
It proved something counterintuitive—that vaccinating children protects their grandparents. Most people think vaccines are individual shields. This showed they're collective ones. That changes everything about how you design public health policy.
And the cardiovascular finding—that flu shots reduce heart deaths by 23 percent. How did he even think to look for that?
He was asking a different question than most researchers. Not just "does the vaccine prevent flu?" but "what else does it prevent?" That's the kind of curiosity that takes decades to develop.
The Loeb Minimum Criteria for antibiotics—that's being used worldwide now. How does a researcher's standard become global practice?
When it works. When hospitals and health systems see it reduces resistance and saves money, they adopt it. But it only spreads if the evidence is bulletproof and the criteria are practical enough to actually implement.
During COVID, he was running mask trials while the world was arguing. That must have been isolating.
It was. But that's the job—to keep generating evidence when everyone else is shouting opinions. The WHO and CDC listened because the data was clean.
What does an award like this actually change for someone like Loeb?
Probably not much in his daily work. But it signals to the next generation of researchers that this kind of rigorous, patient, decades-long commitment to public health matters. That it's worth doing.